Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology
Although nanomedicines have been in the oncology field for almost three decades with the introduction of doxil, only a few nanomedicine products have reached approval. Can nanotechnology be a realistic tool to reduce the number of hospital beds? At present, several clinically approved anti-PD-1/PD-L...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Royal Society
2022-04-01
|
| Series: | Royal Society Open Science |
| Subjects: | |
| Online Access: | https://royalsocietypublishing.org/doi/10.1098/rsos.211991 |